IBAB Stock Overview
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ion Beam Applications SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €12.96 |
| 52 Week High | €17.20 |
| 52 Week Low | €8.26 |
| Beta | 0.90 |
| 1 Month Change | 8.00% |
| 3 Month Change | 23.66% |
| 1 Year Change | -21.36% |
| 3 Year Change | -25.77% |
| 5 Year Change | -19.95% |
| Change since IPO | -74.81% |
Recent News & Updates
Recent updates
Further Upside For Ion Beam Applications SA (EBR:IBAB) Shares Could Introduce Price Risks After 29% Bounce
Mar 25
Is Ion Beam Applications (EBR:IBAB) Using Too Much Debt?
Nov 07Ion Beam Applications (EBR:IBAB) Has Some Way To Go To Become A Multi-Bagger
Oct 05Ion Beam Applications (EBR:IBAB) Is Investing Its Capital With Increasing Efficiency
Jan 31Is Ion Beam Applications (EBR:IBAB) A Risky Investment?
Sep 28Here's Why Shareholders May Want To Be Cautious With Increasing Ion Beam Applications SA's (EBR:IBAB) CEO Pay Packet
Jun 01Ion Beam Applications' (EBR:IBAB) Returns On Capital Are Heading Higher
May 29Does Ion Beam Applications SA (EBR:IBAB) Have A Place In Your Dividend Stock Portfolio?
Apr 20Is Ion Beam Applications (EBR:IBAB) A Risky Investment?
Mar 30Should You Use Ion Beam Applications' (EBR:IBAB) Statutory Earnings To Analyse It?
Feb 10What Type Of Shareholders Make Up Ion Beam Applications SA's (EBR:IBAB) Share Registry?
Jan 06Does This Valuation Of Ion Beam Applications SA (EBR:IBAB) Imply Investors Are Overpaying?
Dec 10Ion Beam Applications' (EBR:IBAB) Shareholders Are Down 64% On Their Shares
Nov 17
Ion Beam Applications SA (EBR:IBAB) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Aug 20Estimating The Intrinsic Value Of Ion Beam Applications SA (EBR:IBAB)
Jul 21Shareholder Returns
| IBAB | BE Medical Equipment | BE Market | |
|---|---|---|---|
| 7D | -2.1% | -0.2% | 1.3% |
| 1Y | -21.4% | -6.2% | -2.9% |
Return vs Industry: IBAB underperformed the Belgian Medical Equipment industry which returned 2.1% over the past year.
Return vs Market: IBAB underperformed the Belgian Market which returned -2.8% over the past year.
Price Volatility
| IBAB volatility | |
|---|---|
| IBAB Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.7% |
| 10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: IBAB's share price has been volatile over the past 3 months.
Volatility Over Time: IBAB's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 2,000 | Olivier Legrain | www.iba-worldwide.com |
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems.
Ion Beam Applications SA Fundamentals Summary
| IBAB fundamental statistics | |
|---|---|
| Market cap | €378.06m |
| Earnings (TTM) | -€9.11m |
| Revenue (TTM) | €428.72m |
0.9x
P/S Ratio-41.5x
P/E RatioIs IBAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBAB income statement (TTM) | |
|---|---|
| Revenue | €428.72m |
| Cost of Revenue | €0 |
| Gross Profit | €428.72m |
| Other Expenses | €437.83m |
| Earnings | -€9.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 23, 2024
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2.12% |
| Debt/Equity Ratio | 47.9% |
How did IBAB perform over the long term?
See historical performance and comparison